IBB holdings (2026)
All 253 positions in iShares Biotechnology ETF, ranked by portfolio weight — led by AMGN at 8.2%. Weights come from the fund's own SEC N-PORT filing and update daily with prices; positions in stocks ChartRow doesn't track still appear, ranked by weight, without returns. Not investment advice.
Weights are the Mar 31, 2026 SEC filing rolled forward on each holding's price move (as of market close, Aug 13, 2026) — an estimate of today, not the filed figure. Switch the table below to see them exactly as filed.
Top 10 holdings#
Sector weights#
Estimated portfolio characteristics#
Estimated by our own bottom-up analysis of the fund's SEC-filed holdings, covering 68% of portfolio weight (60% carries a valid trailing P/E). Funds publish similar figures on their own sites; ours are recomputed daily from public data.
IBB holdings by weight#
101–200 of 253| # | Company | Weight | Price | 1D | YTD | 1Y | Mkt cap |
|---|---|---|---|---|---|---|---|
| 101 | Zai Lab Ltd. | 0.13% | — | — | — | — | — |
| 102 | SMMTSummit Therapeutics Inc. Common Stock | 0.13% | $14.00 | -7.3% | -20.0% | -45.5% | $11B |
| 103 | Nurix Therapeutics, Inc. | 0.13% | — | — | — | — | — |
| 104 | Stoke Therapeutics, Inc. | 0.12% | — | — | — | — | — |
| 105 | Intellia Therapeutics, Inc. | 0.12% | — | — | — | — | — |
| 106 | AnaptysBio, Inc. | 0.12% | — | — | — | — | — |
| 107 | Recursion Pharmaceuticals, Inc. | 0.12% | — | — | — | — | — |
| 108 | Tyra Biosciences, Inc. | 0.12% | — | — | — | — | — |
| 109 | Relay Therapeutics, Inc. | 0.11% | — | — | — | — | — |
| 110 | Amylyx Pharmaceuticals, Inc. | 0.11% | — | — | — | — | — |
| 111 | Novavax, Inc. | 0.11% | — | — | — | — | — |
| 112 | Iovance Biotherapeutics, Inc. | 0.10% | — | — | — | — | — |
| 113 | WaVe Life Sciences Ltd. | 0.10% | — | — | — | — | — |
| 114 | Immunocore Holdings plc | 0.09% | — | — | — | — | — |
| 115 | Novocure Ltd. | 0.09% | — | — | — | — | — |
| 116 | Galapagos NV | 0.09% | — | — | — | — | — |
| 117 | Grifols SA | 0.09% | — | — | — | — | — |
| 118 | Biohaven Ltd. | 0.09% | — | — | — | — | — |
| 119 | Nuvation Bio, Inc. | 0.09% | — | — | — | — | — |
| 120 | AtaiBeckley, Inc. | 0.09% | — | — | — | — | — |
| 121 | Taysha Gene Therapies, Inc. | 0.08% | — | — | — | — | — |
| 122 | Sionna Therapeutics, Inc. | 0.08% | — | — | — | — | — |
| 123 | Trevi Therapeutics, Inc. | 0.08% | — | — | — | — | — |
| 124 | Mesoblast Ltd. | 0.08% | — | — | — | — | — |
| 125 | Corvus Pharmaceuticals, Inc. | 0.08% | — | — | — | — | — |
| 126 | Olema Pharmaceuticals, Inc. | 0.08% | — | — | — | — | — |
| 127 | Rapport Therapeutics, Inc. | 0.08% | — | — | — | — | — |
| 128 | uniQure NV | 0.08% | — | — | — | — | — |
| 129 | Geron Corp. | 0.08% | — | — | — | — | — |
| 130 | Fortrea Holdings, Inc. | 0.07% | — | — | — | — | — |
| 131 | Vir Biotechnology, Inc. | 0.07% | — | — | — | — | — |
| 132 | Xencor, Inc. | 0.07% | — | — | — | — | — |
| 133 | AbCellera Biologics, Inc. | 0.07% | — | — | — | — | — |
| 134 | MBX Biosciences, Inc. | 0.07% | — | — | — | — | — |
| 135 | Maze Therapeutics, Inc. | 0.07% | — | — | — | — | — |
| 136 | CareDx, Inc. | 0.07% | — | — | — | — | — |
| 137 | Theravance Biopharma, Inc. | 0.06% | — | — | — | — | — |
| 138 | Monte Rosa Therapeutics, Inc. | 0.06% | — | — | — | — | — |
| 139 | KalVista Pharmaceuticals, Inc. | 0.06% | — | — | — | — | — |
| 140 | Janux Therapeutics, Inc. | 0.06% | — | — | — | — | — |
| 141 | Pharvaris NV | 0.06% | — | — | — | — | — |
| 142 | MannKind Corp. | 0.06% | — | — | — | — | — |
| 143 | ORIC Pharmaceuticals, Inc. | 0.06% | — | — | — | — | — |
| 144 | Castle Biosciences, Inc. | 0.06% | — | — | — | — | — |
| 145 | Annexon, Inc. | 0.06% | — | — | — | — | — |
| 146 | UroGen Pharma Ltd. | 0.06% | — | — | — | — | — |
| 147 | Kura Oncology, Inc. | 0.06% | — | — | — | — | — |
| 148 | Inhibrx Biosciences, Inc. | 0.06% | — | — | — | — | — |
| 149 | Stevanato Group SpA | 0.06% | — | — | — | — | — |
| 150 | Arbutus Biopharma Corp. | 0.06% | — | — | — | — | — |
| 151 | Septerna, Inc. | 0.05% | — | — | — | — | — |
| 152 | Alto Neuroscience, Inc. | 0.05% | — | — | — | — | — |
| 153 | Bicara Therapeutics, Inc. | 0.05% | — | — | — | — | — |
| 154 | GH Research plc | 0.05% | — | — | — | — | — |
| 155 | ArriVent Biopharma, Inc. | 0.05% | — | — | — | — | — |
| 156 | CytomX Therapeutics, Inc. | 0.05% | — | — | — | — | — |
| 157 | Cullinan Therapeutics, Inc. | 0.05% | — | — | — | — | — |
| 158 | Replimune Group, Inc. | 0.05% | — | — | — | — | — |
| 159 | Precigen, Inc. | 0.05% | — | — | — | — | — |
| 160 | Arvinas, Inc. | 0.05% | — | — | — | — | — |
| 161 | Savara, Inc. | 0.05% | — | — | — | — | — |
| 162 | Ironwood Pharmaceuticals, Inc. | 0.05% | — | — | — | — | — |
| 163 | Phathom Pharmaceuticals, Inc. | 0.04% | — | — | — | — | — |
| 164 | Zevra Therapeutics, Inc. | 0.04% | — | — | — | — | — |
| 165 | Cytek Biosciences, Inc. | 0.04% | — | — | — | — | — |
| 166 | MeiraGTx Holdings plc | 0.04% | — | — | — | — | — |
| 167 | ARS Pharmaceuticals, Inc. | 0.04% | — | — | — | — | — |
| 168 | BioAge Labs, Inc. | 0.04% | — | — | — | — | — |
| 169 | Sana Biotechnology, Inc. | 0.04% | — | — | — | — | — |
| 170 | Rigel Pharmaceuticals, Inc. | 0.04% | — | — | — | — | — |
| 171 | Zenas Biopharma, Inc. | 0.04% | — | — | — | — | — |
| 172 | Compass Pathways plc | 0.04% | — | — | — | — | — |
| 173 | Fulcrum Therapeutics, Inc. | 0.04% | — | — | — | — | — |
| 174 | OPKO Health, Inc. | 0.04% | — | — | — | — | — |
| 175 | Solid Biosciences, Inc. | 0.04% | — | — | — | — | — |
| 176 | 4D Molecular Therapeutics, Inc. | 0.04% | — | — | — | — | — |
| 177 | Prothena Corp. plc | 0.04% | — | — | — | — | — |
| 178 | Emergent BioSolutions, Inc. | 0.04% | — | — | — | — | — |
| 179 | Myriad Genetics, Inc. | 0.03% | — | — | — | — | — |
| 180 | Absci Corp. | 0.03% | — | — | — | — | — |
| 181 | BridgeBio Oncology Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 182 | Perspective Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 183 | Aclaris Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 184 | Altimmune, Inc. | 0.03% | — | — | — | — | — |
| 185 | Vanda Pharmaceuticals, Inc. | 0.03% | — | — | — | — | — |
| 186 | Allogene Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 187 | REGENXBIO, Inc. | 0.03% | — | — | — | — | — |
| 188 | Rocket Pharmaceuticals, Inc. | 0.03% | — | — | — | — | — |
| 189 | Pacific Biosciences of California, Inc. | 0.03% | — | — | — | — | — |
| 190 | Lexeo Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 191 | Alvotech SA | 0.03% | — | — | — | — | — |
| 192 | Contineum Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 193 | Enanta Pharmaceuticals, Inc. | 0.03% | — | — | — | — | — |
| 194 | Lineage Cell Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 195 | Standard BioTools, Inc. | 0.03% | — | — | — | — | — |
| 196 | ADC Therapeutics SA | 0.03% | — | — | — | — | — |
| 197 | Design Therapeutics, Inc. | 0.03% | — | — | — | — | — |
| 198 | Personalis, Inc. | 0.03% | — | — | — | — | — |
| 199 | Atea Pharmaceuticals, Inc. | 0.03% | — | — | — | — | — |
| 200 | Prime Medicine, Inc. | 0.03% | — | — | — | — | — |
Methodology#
Holdings and weights are sourced from the fund's portfolio as disclosed to the SEC on Form N-PORT — a public filing. Portfolio filings are quarterly (public ~60 days after quarter end), so we anchor on the latest one and roll each weight forward daily by that holding's price move, keeping the numbers current between filings; positions in stocks ChartRow doesn't track carry their filed weight unchanged and show "—" where we have no data. Returns are total returns (dividends reinvested). One row per company, not per ticker: when a fund holds more than one share class of the same company (Alphabet's GOOGL and GOOG, for example), we combine them into a single row whose weight is the sum of its classes. Past performance does not predict future returns; not investment advice.
FAQ#
- What are the top 10 holdings of IBB?
- IBB's top 10 holdings are Amgen Inc. (AMGN), 8.2%; Vertex Pharmaceuticals Incorporated (VRTX), 7.9%; Gilead Sciences Inc. (GILD), 7.1%; Regeneron Pharmaceuticals Inc. (REGN), 6.9%; Natera Inc. (NTRA), 3.4%; Revolution Medicines Inc. (RVMD), 2.9%; Argenx SE, 2.8%; Biogen Inc. (BIIB), 2.6%; Alnylam Pharmaceuticals Inc. (ALNY), 2.5%; Illumina Inc. (ILMN), 2.4% — together about 47% of the fund, per its Mar 31, 2026 SEC filing with weights rolled forward to today.
- How many holdings does IBB have?
- iShares Biotechnology ETF (IBB) held 253 positions as of its latest SEC N-PORT filing (Mar 31, 2026).
- How current are IBB's holdings?
- Funds disclose their full portfolio to the SEC on Form N-PORT; the quarter-end report becomes public about 60 days later. ChartRow anchors on the latest public filing (Mar 31, 2026) and rolls each weight forward daily by that holding's price move, so the weights shown estimate today rather than the filing date.
- Is ChartRow affiliated with IBB or BlackRock?
- No. ChartRow is independent and is not affiliated with, sponsored by, or endorsed by BlackRock or iShares Biotechnology ETF. Everything on this page is derived independently from the fund's public SEC filings; fund names and trademarks belong to their owners. For information only — not investment advice.